NEW YORK, Sept. 16, 2018 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.      

Zion Oil & Gas, Inc. (NASDAQ: ZN)
Class Period: March 12, 2018 to July 10, 2018
Lead Plaintiff Deadline: October 9, 2018

Throughout the class period, Zion Oil & Gas, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Zion was either already or was likely to soon become the subject of an U.S. Securities and Exchange Commission investigation; and (2) as a result, Zion’s public statements were materially false and misleading at all relevant times.

On March 27, 2018, Zion issued a statement on Twitter, denying an allegation on the social media platform that there was an SEC investigation of the Company underway. On May 30, 2018, the Company tweeted "There is no SEC investigation into Zion Oil & Gas, Inc." Then on July 11, 2018, Zion announced it had received a subpoena from the SEC to produce documents as part of a fact-finding inquiry. Following this news, shares of Zion fell 11% to close at $3.56 per share on July 12, 2018.

Get additional information about the ZN lawsuit: http://www.kleinstocklaw.com/pslra-c/zion-oil-gas-inc?wire=3

Rockwell Medical, Inc. (NASDAQ: RMTI)
Class Period: November 8, 2017 to June 26, 2018
Lead Plaintiff Deadline: September 25, 2018

The lawsuit alleges Rockwell Medical, Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (1) Rockwell was aware that The Centers for Medicare and Medicaid Services will not pursue Rockwell’s proposal for separate reimbursement for the drug Triferic; (2) the estimated reserves in the first quarter 2018 10-Q are misstated; (3) there was a material weakness in Rockwell’s internal controls over financial reporting; (4) consequently, Rockwell’s internal controls over financial reporting were ineffective during the Class Period; (5) Defendant Chioini withheld material information regarding Triferic from Rockwell’s auditor, corporate counsel and five independent directors of the Board; and (6) as a result, Defendants’ statements about the Company’s business, operations and prospects were materially false and misleading and/or lacked reasonable bases at all relevant times.

Get additional information about the RMTI lawsuit: http://www.kleinstocklaw.com/pslra-c/rockwell-medical-inc?wire=3

Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH)
Class Period: (1) Pursuant and/or traceable to the July 2017 Secondary Offering and/or (2) between March 8, 2017 and February 13, 2018
Lead Plaintiff Deadline: September 25, 2018

The complaint alleges that: (1) Tetraphase was increasing the patient enrollment in its IGNITE3 trial from 1,000 patients to 1,200 patients to meet the trial's primary endpoints; (2) the enrollment of more patients in the trial indicated that the existing population was inadequate to meet the trial's primary endpoints; and (3) consequently, Defendants' statements about Tetraphase's business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis.

Get additional information about the TTPH lawsuit: http://www.kleinstocklaw.com/pslra-c/tetraphase-pharmaceuticals-inc?wire=3

Helios and Matheson Analytics Inc. (NASDAQCM: HMNY)
Class Period: August 15, 2017 to July 26, 2018
Lead Plaintiff Deadline: October 1, 2018

Throughout the class period, Helios and Matheson Analytics Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Helios was touting MoviePass’ valuation and path to profitability; (ii) MoviePass’ business model was not sustainable, (iii) consequently, Helios would run out of cash, (iv) Defendants’ actions were only reducing shareholder value, and (v) as a result of the foregoing, Defendants’ statements about Helios’ business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

Get additional information about the HMNY lawsuit: http://www.kleinstocklaw.com/pslra-c/helios-and-matheson-analytics-inc?wire=3

GDS Holdings Limited (NASDAQ: GDS)
Class Period: November 2, 2016 to July 31, 2018
Lead Plaintiff Deadline: October 1, 2018

The lawsuit alleges that throughout the class period, GDS Holdings Limited made materially false and/or misleading statements and/or failed to disclose that: (1) the Company has overstated its utilization and occupancy rates; (2) the Company has made acquisitions with related parties at inflated prices; (3) it has used suspect capital and debt raisings despite large off-shore cash reserves; (4) it has adopted unorthodox accounts receivable and payable practices; and (5) that, as a result of the foregoing, Defendant's statements about GDS' business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.

Get additional information about the GDS lawsuit: http://www.kleinstocklaw.com/pslra-c/gds-holdings-limited?wire=3

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Joseph Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.